Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy) | Zendy

Ada C. Stefanescu Schmidt | Zendy; Larry S. Dean | Zendy; Donald E. Cutlip | Zendy; Robert W. Yeh | Zendy; Ralph B. D’Agostino | Zendy; Joseph M. Massaro | Zendy; Wen-Hua Hsieh | Zendy; Laura Mauri | Zendy

Open Access

Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy)

Author(s) -

Ada C. Stefanescu Schmidt,

Larry S. Dean,

Donald E. Cutlip,

Robert W. Yeh,

Ralph B. D’Agostino,

Joseph M. Massaro,

Wen-Hua Hsieh,

Laura Mauri

Publication year - 2017

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.116.024835

Subject(s) - medicine , thienopyridine , discontinuation , myocardial infarction , prasugrel , cardiology , platelet aggregation inhibitor , clopidogrel , aspirin

Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) risk and increases bleeding risk in comparison with aspirin alone. The hazard associated with late thienopyridine discontinuation and risk factors for MI after discontinuation are poorly defined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research